NovoBiome and Inserm begin collaboration into human intestinal physiology
pharmafile | February 22, 2022 | News story | Manufacturing and Production |
NovoBiome, a drug discovery company developing breakthrough Live Biotherapeutics Products, announced that it has signed a new collaboration with the French National Institute of Health and Medical Research (Inserm).
This collaboration will see the development of an innovative intestinal organoid on a chip technology that will complete the functionality of NovoBiome’s NovoSift Platform, which analyses the sybiotic relationship between the microbiota and the human intestine.
This new collaboration will allow the scaling up of NovoBiome’s ambition to evaluate the mechanisms at work after the oral administration of a food, a drug, or an LBP1 aiming to modulate the intestinal microbiota.
Pierre-Yves Mousset, CEO of NovoBiome, said: “The implications of understanding the host-microbiota relationships are considerable in human health. However, this major part of physiology is currently a “black box” that the exceptional cooperation between NovoBiome and two french academic structures of excellence, Inserm and INRAE, will seek to decipher. We are extremely proud of the trust placed in us and are particularly eager to see the first results.
“Working in close partnership with NovoBiome represents a unique opportunity to accelerate and foster the transfer of discoveries on health beneficial effects of the gut microbiota, from the lab to the benefit of patients and of the overall general population,” commented Michel Neunlist director of the TENS unit at Inserm.
NovoBiome is a biotech company developing Live Biotherapeutics Products, a novel and emerging class of drugs, which are defined by the EMA as medicinal products containing living mico-organisms such as bacteria or yeasts.
Lina Adams
